Comparative Pharmacology
Head-to-head clinical analysis: AMMONIA N 13 versus CHROMITOPE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMMONIA N 13 versus CHROMITOPE SODIUM.
AMMONIA N 13 vs CHROMITOPE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia N 13 is a radioactive diagnostic agent that is used as a tracer for positron emission tomography (PET) imaging. After intravenous injection, it distributes in the body and is taken up by cells, particularly in the myocardium and brain, via active transport and passive diffusion. Its accumulation reflects regional blood flow and metabolic activity.
Chromitope sodium (sodium chromate Cr-51) is a radioactive diagnostic agent. Chromium-51 is incorporated into red blood cells by binding to hemoglobin. Following intravenous injection, the labeled RBCs distribute within the vascular compartment. The radioactive decay allows measurement of RBC mass and survival via scintillation counting. No pharmacological effect; acts solely as a tracer.
1110-1850 MBq (30-50 mCi) intravenous bolus for PET imaging; single dose per imaging session. No repeated dosing within 24 hours.
Adult: 1-5 mCi (37-185 MBq) intravenously as a single dose for renal imaging. Dose depends on scan type and patient weight.
None Documented
None Documented
9–12 minutes (blood) for ammonia; incorporation into glutamine may extend effective half-life for imaging purposes; rapid clearance limits toxicity.
Terminal half-life 70-90 minutes (prolonged in renal impairment to >12 hours).
Primary renal excretion; >95% eliminated as unchanged ammonia via glomerular filtration and tubular secretion. Minimal biliary/fecal excretion.
Primarily renal (50-70% as unchanged drug over 24 hours); minor biliary/fecal (10-20%).
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical